Cytokinetics, Incorporated
Cytokinetics, Incorporated (CYTK) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · CYTK · as of Jun 8, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
77
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Cytokinetics, Incorporated insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
CYTK insider buying and selling by quarter
CYTK insider selling · CYTK insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · CYTK ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
CYTK executive sell shares · CYTK board member insider trading · CYTK insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Jun 1, 2026 | Kaye Edward M. MD Director | Sale | 2,933 | $223K | Form 4 |
| Jun 1, 2026 | Callos Andrew EVP, Chief Commercial Officer | Option | 15,000 | $349K | Form 4 |
| Jun 1, 2026 | Callos Andrew EVP, Chief Commercial Officer | Sale | 15,000 | $1.11M⚡ | Form 4 |
| Jun 1, 2026 | PARSHALL B LYNNE Director | Sale | 5,000 | $370K | Form 4 |
| May 27, 2026 | Blum Robert I President & CEO · Director | Sale | 7,500 | $579K | Form 4 |
| May 27, 2026 | Bhanji Muna Director | Award | 2,851 | — | Form 4 |
| May 27, 2026 | Daly James M Director | Award | 2,851 | — | Form 4 |
| May 27, 2026 | Harrington Robert Arthur Director | Award | 2,851 | — | Form 4 |
| May 27, 2026 | HENDERSON JOHN T Director | Award | 2,851 | — | Form 4 |
| May 27, 2026 | Kaye Edward M. MD Director | Award | 2,851 | — | Form 4 |
| May 27, 2026 | PARSHALL B LYNNE Director | Award | 2,851 | — | Form 4 |
| May 27, 2026 | Landry Robert E Director | Award | 2,851 | — | Form 4 |
| May 27, 2026 | WIERENGA WENDELL Director | Award | 2,851 | — | Form 4 |
| May 27, 2026 | Wysenski Nancy Director | Award | 2,851 | — | Form 4 |
| May 19, 2026 | Malik Fady Ibraham EVP Research & Development | Option | 3,500 | $27K | Form 4 |
| May 19, 2026 | Malik Fady Ibraham EVP Research & Development | Sale | 3,500 | $265K | Form 4 |
| May 14, 2026 | Blum Robert I President & CEO · Director | Sale | 7,500 | $584K | Form 4 |
| May 5, 2026 | Malik Fady Ibraham EVP Research & Development | Option | 3,500 | $27K | Form 4 |
| May 5, 2026 | Malik Fady Ibraham EVP Research & Development | Sale | 3,500 | $271K | Form 4 |
| May 5, 2026 | WIERENGA WENDELL Director | Option | 4,032 | $50K | Form 4 |
| May 5, 2026 | WIERENGA WENDELL Director | Sale | 4,032 | $302K | Form 4 |
| May 5, 2026 | Lee Sung EVP, Chief Financial Officer | Sale | 23,906 | $1.84M⚡ | Form 4 |
| May 5, 2026 | HENDERSON JOHN T Director | Option | 20,000 | $152K | Form 4 |
| May 5, 2026 | HENDERSON JOHN T Director | Sale | 20,000 | $1.52M⚡ | Form 4 |
| May 5, 2026 | Callos Andrew EVP, Chief Commercial Officer | Option | 11,333 | $443K | Form 4 |
Callos Andrew
EVP, Chief Commercial Officer
Date
Jun 1
Shares
15,000
Price
$23.26
Value
$349K
Callos Andrew
EVP, Chief Commercial Officer
Date
Jun 1
Shares
15,000
Price
$74.08
Value
$1.11M ⚡
Blum Robert I
President & CEO · Director
Date
May 27
Shares
7,500
Price
$77.21
Value
$579K
Malik Fady Ibraham
EVP Research & Development
Date
May 19
Shares
3,500
Price
$7.80
Value
$27K
Malik Fady Ibraham
EVP Research & Development
Date
May 19
Shares
3,500
Price
$75.69
Value
$265K
Blum Robert I
President & CEO · Director
Date
May 14
Shares
7,500
Price
$77.92
Value
$584K
Malik Fady Ibraham
EVP Research & Development
Date
May 5
Shares
3,500
Price
$7.80
Value
$27K
Malik Fady Ibraham
EVP Research & Development
Date
May 5
Shares
3,500
Price
$77.37
Value
$271K
Lee Sung
EVP, Chief Financial Officer
Date
May 5
Shares
23,906
Price
$76.87
Value
$1.84M ⚡
Callos Andrew
EVP, Chief Commercial Officer
Date
May 5
Shares
11,333
Price
$39.13
Value
$443K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About CYTK insider trading
CYTK insider trades
Cytokinetics, Incorporated (CYTK) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Callos Andrew (EVP, Chief Commercial Officer), Malik Fady Ibraham (EVP Research & Development), Blum Robert I (President & CEO · Director). Over the past 12 months, 5 insiders have filed transactions with the SEC. CYTK insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Cytokinetics, Incorporated's institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
CYTK insider trading · 5 questionsThe insiders of Cytokinetics, Incorporated (CYTK) include executives and directors such as Callos Andrew (EVP, Chief Commercial Officer), Malik Fady Ibraham (EVP Research & Development), Blum Robert I (President & CEO · Director), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026